Nanomix
Emeryville · Founded 2000
About Nanomix
Nanomix's leadership in nano particle based electronic sensors has enabled the development of eLab, the next generation of Point of Care testing systems where superior performance and rapid results can both be achieved in virtually any setting. Assays run on eLab provide actionable diagnostic information in 10 minutes or less and can be used to accelerate critical care or to make decisions to treat patients in place or transport them to the hospital. Use of mobile POC diagnostics is essential to reducing healthcare system costs while improving the patient experience and outcome. The Nanomix mobile diagnostic platform performs multiple in-vitro diagnostic and enzymatic assays simultaneously from a single whole-blood sample. The compact size of the electronic instrument and disposable test cartridge can be configured to run a wide variety of tests using muitple assay techniques. Initial system assays address critical cardiac care and sepsis screening.
Company Facts
- Founded: 2000
- Legal name: Nanomix Corp.
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $49.3M
- Funding stage: IPO
- Last round: Series Unknown (Jan 2014)
- Website: nano.com
- Phone: +1 (510)428-5300
Social Profiles
Canonical: https://fsome.com/organization/nanomix-8315578 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.